Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

Sanyal, Arun J.; Natta, Mark L. Van; Clark, Jeanne M.; Neuschwander‐Tetri, Brent A.; Diehl, Anna Mae; Dasarathy, Srinivasan; Loomba, Rohit; Chalasani, Naga; Kowdley, Kris V.; Hameed, Bilal; Wilson, Laura; Yates, Katherine P.; Belt, Patricia; Lazo, Mariana; Kleiner, David E.; Behling, Cynthia; Tonascia, James

doi:10.1056/nejmoa2029349

Cited by 565 publications

(487 citation statements)

References 27 publications

Supporting

Mentioning

410

Contrasting

Unclassified

Order By: Relevance

“…[ 3 ] Besides, a recent prospective study showed that all-cause mortality increased with increasing fibrosis stage in NAFLD patients. [ 4 ] While liver biopsy remains the only accepted method to diagnose NASH and the reference standard to evaluate fibrosis, it is an invasive procedure and cannot be widely applied. It is also ill suited as a monitoring test.…”

Section: Introductionmentioning

confidence: 99%

Non-invasive tests of non-alcoholic fatty liver disease

Zhang

Lin

et al. 2022

Chinese Medical Journal

View full text Add to dashboard Cite

For the detection of steatosis, quantitative ultrasound imaging techniques have achieved great progress in past years. Magnetic resonance imaging proton density fat fraction is currently the most accurate test to detect hepatic steatosis. Some blood biomarkers correlate with non-alcoholic steatohepatitis, but the accuracy is modest. Regarding liver fibrosis, liver stiffness measurement by transient elastography (TE) has high accuracy and is widely used across the world. Magnetic resonance elastography is marginally better than TE but is limited by its cost and availability. Several blood biomarkers of fibrosis have been used in clinical trials and hold promise for selecting patients for treatment and monitoring treatment response. This article reviews new developments in the non-invasive assessment of non-alcoholic fatty liver disease (NAFLD). Accumulating evidence suggests that various non-invasive tests can be used to diagnose NAFLD, assess its severity, and predict the prognosis. Further studies are needed to determine the role of the tests as monitoring tools. We cannot overemphasize the importance of context in selecting appropriate tests.

show abstract

Section: Introductionmentioning

confidence: 99%

Non-invasive tests of non-alcoholic fatty liver disease

Zhang

Lin

et al. 2022

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

“…Nevertheless, some newer glucose-lowering drugs that are widely used for the treatment of T2DM, such as peroxisome proliferatoractivated receptor (PPAR) agonists, including thiazolidinediones (TZDs), glucagonlike peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors, have shown promising results for the treatment of NAFLD and NASH. [32][33][34][35][36][37] We therefore carried out an updated narrative review to briefly summarize the efficacy and safety of the aforementioned newer glucose-lowering drugs in adults with NAFLD or NASH. The results of principal randomized clinical trials examining the efficacy of these drugs for specifically treating adults with biopsy-proven NASH, regardless of the presence or absence of T2DM, are summarized in Table 1.…”

Section: Introductionmentioning

confidence: 99%

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Miao¹,

Xu²,

Targher³

et al. 2022

Clin Mol Hepatol

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucoselowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.

show abstract

“…diabetes, hypertension, hyperlipidemia, and obesity, isolating the impact of the liver disease in itself is difficult [8]. Though liver fibrosis severity has been implicated as a determinant factor for the increased risk of CVD [9,10], conflicting evidence exists [11]. Proportionally, however, CVD constitutes a larger problem as compared to liver-related disease in the milder spectrum of disease [6,9,10,12].…”

Section: Introductionmentioning

confidence: 99%